Trial Profile
A Feasibility Study of Carboplatin/Paclitaxel/Nivolumab with Concurrent Thoracic Radiotherapy in Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 05 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 29 Jul 2020 Planned End Date changed from 31 Aug 2022 to 28 Feb 2023.
- 26 Mar 2020 Planned End Date changed from 28 Feb 2022 to 31 Aug 2022.